Medications for Dry Eye Syndrome
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Dry Eye Syndrome.
Found 3 Approved Drugs for Dry Eye Syndrome
CycloSPORINE
Brand Names
Restasis MultiDose, Neoral, VEVYE, CEQUA, Sandimmune, Restasis, Verkazia, Gengraf
CycloSPORINE
Brand Names
Restasis MultiDose, Neoral, VEVYE, CEQUA, Sandimmune, Restasis, Verkazia, Gengraf
Form: Injection, Emulsion, Capsule, Solution
Method of administration: Oral, Intravenous, Ophthalmic, Topical
FDA approval date: November 14, 1983
Classification: Calcineurin Inhibitor Immunosuppressant
Kidney, Liver, and Heart Transplantation Cyclosporine capsules (modified) is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules (modified) has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Cyclosporine capsules (modified) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine capsules (modified) can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. Psoriasis Cyclosporine capsules (modified) is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. While rebound rarely occurs, most patients will experience relapse with cyclosporine capsules (modified) as with other therapies upon cessation of treatment.
Hydrchloride
Brand Names
Salagen, Qlosi, VUITY
Hydrchloride
Brand Names
Salagen, Qlosi, VUITY
Form: Tablet, Solution
Method of administration: Oral, Ophthalmic
FDA approval date: February 21, 1996
Classification: Cholinergic Receptor Agonist
Pilocarpine hydrochloride tablets, USP are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.
Lacrisert
Generic Name
Hydroxypropyl
Lacrisert
Generic Name
Hydroxypropyl
Form: Insert
Method of administration: Ophthalmic
FDA approval date: June 01, 1981
Classification: Demulcent
LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions.
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances